Sunderland, UK-based Arquer Diagnostics has appointed Nadia Whittley as its new chief executive officer with immediate effect.
Whittley joins the oncology diagnostic specialist from Tefen Management Consulting, where she was partner and managing director, Europe, responsible for the strategic direction of the company’s life science business unit across EMEA.
Previously, she has served as chief executive of Alium Medical, a UK-based global supply service, managing director of medical devices, EMEA at Allergan, and marketing director for interventional cardiology, EMEA at Boston Scientific International.
Dr Sandy Primrose, chairman of Arquer Diagnostics, said: “I would like to welcome Nadia and am delighted that we have someone with her commercial background as our new chief executive officer.
“Her experience of successfully launching new technologies across multiple regions and her knowledge of the sector make her a real asset to the business, particularly as we move forward to commercialise our MCM5-ELISA diagnostic test.”